10.16

1.70% 0.17

After Hours: 10.16

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $10.16, with a volume of 621.95K. It is up +1.70% in the last 24 hours and down -4.06% over the past month. Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Previous Close:

$9.99

Open:

$9.87

24h Volume:

621.95K

Relative Volume:

0.50

Market Cap:

$600.21M

Revenue:

Net Income/Loss:

$-153.16M

P/E Ratio:

-2.7534

EPS:

-3.69

Net Cash Flow:

$-134.48M

1W Performance:

+2.42%

1M Performance:

-4.06%

6M Performance:

+30.09%

1Y Performance:

-13.75%

1-Day Range:

$9.78

$10.25

1-Week Range:

$9.41

$10.70

52-Week Range:

$5.68

$13.33

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (625)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

111

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

CGEM's Discussions on Twitter

Compare CGEM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEM Cullinan Therapeutics Inc	10.16	590.17M	0	-153.16M	-134.48M	-3.69
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-21-25	Resumed	H.C. Wainwright	Buy
Jun-11-25	Resumed	Stifel	Buy
Oct-24-24	Initiated	UBS	Buy
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

Dec 31, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 3.9%What's Next? - MarketBeat

Dec 31, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 31, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 31, 2025

Dec 29, 2025

Nadim Ahmed Sells 9,922 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat

Dec 29, 2025

Dec 25, 2025

Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat

Dec 25, 2025

Dec 23, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat

Dec 23, 2025

Dec 22, 2025

Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus

Dec 22, 2025

Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $13,463.45 in Stock - MarketBeat

Dec 22, 2025

Cullinan Therapeutics CSO Sells Shares - TradingView — Track All Markets

Dec 22, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock - Defense World

Dec 22, 2025

Dec 21, 2025

Cullinan Therapeutics (CGEM) Price Target Increased by 19.75% to 32.84 - Nasdaq

Dec 21, 2025

Will Cullinan Therapeutics Inc. stock deliver shareholder value2025 Price Targets & Weekly High Potential Stock Alerts - ulpravda.ru

Dec 21, 2025

Dec 20, 2025

Cullinan Therapeutics price target raised to $34 from $25 at Wedbush - MSN

Dec 20, 2025

Cullinan Therapeutics Earnings Notes - Trefis

Dec 20, 2025

Cullinan Therapeutics shows rising price performance with jump to 93 RS rating - MSN

Dec 20, 2025

Dec 19, 2025

Is Cullinan Therapeutics Inc. stock a contrarian buy2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - Улправда

Dec 19, 2025

Jacquelyn Sumer Sells 3,480 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat

Dec 19, 2025

Jeffrey Alan Jones Sells 4,632 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat

Dec 19, 2025

Cullinan Therapeutics Executives Sell Shares for Tax Obligations - TradingView — Track All Markets

Dec 19, 2025

Officer Michaelson Files To Sell 1,345 Of Cullinan Therapeutics Inc [CGEM] - TradingView — Track All Markets

Dec 19, 2025

How Cullinan Therapeutics Inc. stock reacts to inflationary pressures2025 Sector Review & Reliable Intraday Trade Plans - Улправда

Dec 19, 2025

Jobs Data: Will Cullinan Therapeutics Inc. stock deliver better than expected guidanceMarket Trend Summary & Technical Buy Zone Confirmations - Улправда

Dec 19, 2025

Dec 18, 2025

Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail

Dec 18, 2025

Dec 17, 2025

Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely? - Yahoo Finance

Dec 17, 2025

Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data - Investing.com Nigeria

Dec 17, 2025

Dec 16, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 2,148 Shares of Stock - MarketBeat

Dec 16, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 995 Shares - MarketBeat

Dec 16, 2025

Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Finviz

Dec 16, 2025

Dec 15, 2025